newsletter

Xeomin

First there was Botox, then there was Dysport, and now there is Xeomin (incobotulinumtoxinA). The Food and Drug Administration (FDA) recently approved this new botulinum toxin type A product to treat severe frown lines or "11's" between the eyebrows. Xeomin is manufactured by Merz Pharmaceuticals, and has been used by more than 84,000 people worldwide. It is now approved for use in 20 countries.

Like other drugs in this category, Xeomin works by paralyzing wrinkles. It blocks the signals from the nerves to the muscles. As a result, the targeted muscle cannot contract.

Xeomin versus Botox and Dysport

Botox, Dysport and Xeomin have a lot in common, but they also have some important differences. Unlike its predecessors, Xeomin does not need to be refrigerated. This may be an advantage when it comes to distribution. What's more, Xeomin is "naked." There are no additives — just botulinum toxin type A. This may lessen a patient's likelihood of developing antibodies to Xeomin. When your body senses a foreign invader, it responds by creating antibodies and launching an attack. If this were to occur with a neurotoxin such as botulinum toxin type A, it may not have its desired effects.

Xeomin is said to be more like Botox than Dysport. It takes about one week for the full effects of Xeomin injections to be realized, and once this occurs the results last from three to six months. Dysport, Xeomin and Botox should not be used interchangeably.

If you are interested in Xeomin injections, consult with Dr. Yuriy Yagudin to explore your candidacy.

Legal disclaimer:

The content on this website is provided for informational purposes only, and is not intended in any way to substitute professional medical advice during an in office consultation and examination by the physician. Any photos from this web site with text “Copyright Dermacare Medical PC” on them are not allowed to be copied and reprinted in any way without written permission from Dermacare Medical PC.